1. Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis.
- Author
-
Takatsuka D, Sawaki M, Hattori M, Yoshimura A, Kotani H, Kataoka A, Horisawa N, Ozaki Y, Endo Y, Nozawa K, and Iwata H
- Subjects
- Humans, Female, Cyclin-Dependent Kinase 4, Protein Kinase Inhibitors therapeutic use, Antineoplastic Combined Chemotherapy Protocols adverse effects, Clinical Trials, Phase II as Topic, Randomized Controlled Trials as Topic, Breast Neoplasms metabolism
- Abstract
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been approved for breast cancer (BC) treatment. Several trials suggested that arthralgia was reduced in patients treated with ET plus CDK4/6i compared with that in those with ET-alone. We aimed to compare arthralgia rates in BC patients treated with/without CDK4/6i. We reviewed randomized controlled phase II/III trials investigating CDK4/6i with ET in hormone receptor-positive and epidermal growth factor 2-negative BC. Publications were retrieved from PubMed from January 2014 to April 2021. We compared arthralgia rates between patients who were administered ET plus CDK4/6i (CDK4/6i group) and those treated with ET-alone (control group). We reviewed 12 trials that reported data on adverse effects for arthralgia. These trials included 17,440 patients (9255 in the CDK4/6i group and 8185 in the control group). The arthralgia rate in the CDK4/6i group was significantly lower than that in the control group (27.6% vs. 34.8%, p < .001), especially in early BC (28.8% vs. 37.3%, p < .001). These suggested that the arthralgia rate in patients treated with ET plus CDK4/6i was lower than that in patients treated with ET-alone and that CDK4/6i may decrease the arthralgia rate in BC patients treated with ET, especially in early BC., (© 2022 John Wiley & Sons Australia, Ltd.)
- Published
- 2023
- Full Text
- View/download PDF